Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CLINIMIX E 2.75/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER vs AMINO ACIDS
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Clinimix E 2.75/25 provides amino acids for protein synthesis and dextrose for caloric support in parenteral nutrition. Amino acids serve as substrates for protein synthesis, while dextrose provides a source of glucose for energy metabolism, preventing catabolism and promoting anabolism.
Amino acids are building blocks for protein synthesis and serve as precursors for neurotransmitters, hormones, and other nitrogenous compounds. They modulate nitrogen balance and support cellular repair and growth.
Parenteral nutrition for patients requiring supplemental or total nutritional support,Off-label: Not typically used off-label due to specific formulation
Total parenteral nutrition (TPN) for patients unable to ingest or absorb adequate nutrients,Supplementation in metabolic disorders (e.g., urea cycle disorders, maple syrup urine disease),Treatment of negative nitrogen balance due to trauma, burns, or surgery
Intravenous administration: Adult dose based on protein and electrolyte requirements; typical infusion rate not to exceed 4 mg/kg/min of dextrose. Daily dose should not exceed 2.5 g/kg amino acids or 25 g/kg dextrose.
1-2 g/kg/day as continuous IV infusion or as a component of parenteral nutrition.
Amino acids: not applicable (endogenous turnover). Dextrose: ~1-2 hours (exogenous glucose). Electrolytes: dependent on renal function; not traditionally defined.
Variable; endogenous amino acids: 10–30 min for clearance from plasma; administered doses: distribution half-life ~5–10 min, terminal elimination half-life ~15–30 min, reflecting rapid metabolic utilization and renal reabsorption.
Amino acids are metabolized via transamination and deamination in the liver; dextrose undergoes glycolysis and enters the citric acid cycle. Electrolytes are excreted or reabsorbed renally.
Amino acids are metabolized primarily in the liver via transamination, deamination, and urea cycle. Specific pathways exist for each amino acid; excess nitrogen is converted to urea.
Amino acids: renal elimination of metabolites and urea. Dextrose: metabolized to CO2 and water, exhaled via lungs. Electrolytes: primarily renal (90-95%), minor fecal (<5%). No significant biliary excretion.
Renal: >95% as amino acids and metabolites, primarily reabsorbed; <5% unchanged. Fecal/biliary: negligible (<1%).
Amino acids: negligible (<5% bound). Dextrose: negligible. Electrolytes: variable; calcium ~40% bound to albumin, magnesium ~30% bound to albumin, potassium and sodium minimally bound (<5%).
Minimal for most amino acids (<10%); albumin and globulins bind tryptophan and aromatic amino acids (~80–90% for tryptophan).
Amino acids: total body water (~0.5-0.7 L/kg). Dextrose: total body water (~0.2 L/kg initially). Electrolytes: sodium ~0.6 L/kg, potassium ~0.4 L/kg, calcium ~0.2 L/kg, magnesium ~0.3 L/kg.
0.4–0.6 L/kg (total body water); reflects equilibration with intracellular and extracellular fluid compartments.
Not applicable; administered as intravenous infusion only (bioavailability 100% by IV route). No oral bioavailability.
Oral: ~90–100% (active transport across intestinal mucosa); IV: 100%.
In GFR 30-59 m L/min: reduce amino acid dose by 50% and monitor electrolytes closely. If GFR <30 m L/min: avoid or use only with extreme caution, typically restrict protein to 0.6-0.8 g/kg/day and adjust electrolytes per serum levels.
For GFR <30 m L/min: reduce dose to 0.5-1 g/kg/day; monitor serum amino acids and nitrogen balance.
Child-Pugh Class A: no adjustment necessary. Child-Pugh B: reduce amino acid dose to 0.8-1.2 g/kg/day. Child-Pugh C: avoid due to risk of encephalopathy; if essential, restrict to 0.5-0.7 g/kg/day with branched-chain amino acid enrichment.
Child-Pugh B or C: avoid standard formulations; use branched-chain amino acid (BCAA)-enriched solutions at 0.8-1.2 g/kg/day.
Neonates and infants: 2-3 g/kg/day amino acids and 10-15 g/kg/day dextrose, titrating gradually. Children: 1-2 g/kg/day amino acids and 5-10 g/kg/day dextrose; rate not to exceed 0.2-0.4 g/kg/h dextrose. Adjust electrolytes per daily requirements.
0.5-2 g/kg/day IV; titrate based on age, growth, and metabolic needs.
Elderly patients: start at lower end of dose range; monitor renal function and serum electrolytes closely. Typical amino acid dose 1.0-1.2 g/kg/day, dextrose dose adjusted to avoid hyperglycemia; infusion rate not to exceed 2 mg/kg/min.
Initiate at 0.8 g/kg/day IV, adjust based on renal function and nitrogen balance; monitor for fluid overload.
Not for use in patients with severe electrolyte imbalances, severe liver disease, or severe renal impairment. May cause hyperglycemia, electrolyte abnormalities, or volume overload. Must be used under medical supervision.
Patients receiving amino acid infusions should be monitored for metabolic acidosis, hyperammonemia, and renal function impairment. Solutions with electrolytes should not be used in patients with severe electrolyte imbalances.
Monitor serum glucose, electrolytes, fluid status, and renal function,Risk of hyperglycemia in diabetic patients,Risk of electrolyte disturbances including hyperkalemia, hypercalcemia, and hyperphosphatemia,Avoid in patients with galactosemia or fructose intolerance,Use caution in hepatic or renal impairment
Use with caution in patients with renal impairment, hepatic failure, heart failure, or metabolic acidosis. Monitor serum electrolytes, blood urea nitrogen, and ammonia levels. Avoid rapid infusion to prevent hyperosmolarity and venous thrombosis.
Hypersensitivity to any component,Severe electrolyte imbalance,Severe liver disease (e.g., hepatic coma),Severe renal impairment (anuria, oliguria),Galactosemia,Fructose intolerance
Hypersensitivity to any component, inborn errors of amino acid metabolism (e.g., phenylketonuria) without specific formula, severe hyperammonemia, anuria, or metabolic acidosis.
No direct food interactions as this is an intravenous product. However, oral intake may be restricted or monitored due to underlying medical conditions (e.g., diabetes, renal failure). Ensure consistent carbohydrate intake if transitioning to oral feeding.
No significant food interactions; however, enteral nutrition should be managed to avoid excessive protein intake. Patients with phenylketonuria must avoid phenylalanine-containing amino acid solutions.
CLINIMIX E 2.75/25 (amino acids, dextrose, electrolytes, calcium) is a parenteral nutrition solution. No adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted. However, amino acids and dextrose are endogenous substances; electrolyte imbalances can cause fetal harm. In first trimester: avoid unless maternal benefit outweighs risk; deficiencies in essential nutrients may be teratogenic. Second/third trimester: use only if clearly needed; monitor for hyperglycemia (risk of fetal macrosomia, neonatal hypoglycemia).
Amino acids are essential nutrients; at physiologic doses, no teratogenic risk is established. At supraphysiologic doses, theoretical risk of metabolic imbalance exists. No trimester-specific human data; animal studies show no teratogenicity at standard doses.
Excretion into breast milk: unknown. Components are endogenous, so transfer is likely minimal. No specific M/P ratio available. Considered probably compatible with breastfeeding, but monitor infant for electrolyte disturbances if maternal levels are abnormal.
Amino acids are normal constituents of breast milk; supplementation likely results in increased maternal levels but endogenous secretion maintains relatively constant milk levels. M/P ratio not established; generally considered compatible with breastfeeding at recommended doses.
Pregnancy requires increased nutritional demands; no specific dose adjustments are established. Monitor blood glucose due to insulin resistance; consider reducing dextrose infusion if hyperglycemia develops. Adjust electrolytes based on serial monitoring. Start at lower infusion rates and titrate slowly.
No specific dose adjustments required for enteral amino acids. For parenteral nutrition, consider increased requirements in third trimester (protein needs up to 1.5 g/kg/day). Adjust based on maternal weight gain, renal function, and metabolic monitoring.
CLINIMIX E 2.75/25 is a dual-chamber bag containing amino acids and dextrose with electrolytes, including calcium. Do not use if seals are broken or if solution is discolored. Must be administered via central line due to high dextrose concentration (25%). Avoid simultaneous administration with ceftriaxone due to calcium-ceftriaxone precipitation risk. Monitor serum electrolytes, blood glucose, and liver function tests closely. Not for use in patients with severe hepatic or renal impairment.
Amino acid infusions should be administered via central line if osmolarity > 900 m Osm/L to prevent thrombophlebitis. Monitor serum ammonia and BUN in patients with hepatic or renal impairment. Use with caution in patients with inborn errors of amino acid metabolism.
This medication provides nutrition through a vein and must be given by a healthcare professional.,Report any signs of infection at the IV site (redness, swelling, pain) or allergic reactions (rash, itching, difficulty breathing).,Inform your healthcare provider if you have a history of diabetes, kidney disease, or liver problems.,This solution contains added calcium; avoid taking additional calcium supplements without doctor approval.,You may experience changes in blood sugar; symptoms of high or low blood sugar (e.g., excessive thirst, urination, shakiness) should be reported.
This medication provides essential building blocks for protein synthesis.,Report any signs of allergic reaction such as rash, itching, or difficulty breathing.,Inform your doctor if you have liver or kidney disease.,Do not take other protein supplements unless directed by your healthcare provider.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CLINIMIX E 2.75/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER vs AMINO ACIDS, answered by our medical review team.
CLINIMIX E 2.75/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER is a Parenteral Nutrition Solution that works by Clinimix E 2.75/25 provides amino acids for protein synthesis and dextrose for caloric support in parenteral nutrition. Amino acids serve as substrates for protein synthesis, while dextrose provides a source of glucose for energy metabolism, preventing catabolism and promoting anabolism.. AMINO ACIDS is a Parenteral Nutrition Solution that works by Amino acids are building blocks for protein synthesis and serve as precursors for neurotransmitters, hormones, and other nitrogenous compounds. They modulate nitrogen balance and support cellular repair and growth.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CLINIMIX E 2.75/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER and AMINO ACIDS depend on the specific clinical indication. These are both Parenteral Nutrition Solution agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CLINIMIX E 2.75/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER is: Intravenous administration: Adult dose based on protein and electrolyte requirements; typical infusion rate not to exceed 4 mg/kg/min of dextrose. Daily dose should not exceed 2.5 g/kg amino acids or 25 g/kg dextrose.. The standard adult dose of AMINO ACIDS is: 1-2 g/kg/day as continuous IV infusion or as a component of parenteral nutrition.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CLINIMIX E 2.75/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER and AMINO ACIDS in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CLINIMIX E 2.75/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER is classified as Category C. CLINIMIX E 2.75/25 (amino acids, dextrose, electrolytes, calcium) is a parenteral nutrition solution. No adequate and well-controlled studies in pregnant women. Animal reproduction. AMINO ACIDS is classified as Category C. Amino acids are essential nutrients; at physiologic doses, no teratogenic risk is established. At supraphysiologic doses, theoretical risk of metabolic imbalance exists. No trimest. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.